Skip to main navigation Skip to search Skip to main content

Cost Effectiveness Analysis of imatinib mesylate for the treatment of patients with unresectable and/or metastic gastro-intestinal stromal tumours

Research output: Contribution to journalArticle

Original languageEnglish
JournalHealth Technology Assessment
Volume9
Issue number25
Publication statusPublished - 1 Jan 2005

Cite this